Back to Trial

Oracle Runs

Oracle findings and outcome history for A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine (NCT04975893).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:37 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Exact Phase 2 extension trial NCT04975893 has a trial-specific favorable readout: both the journal abstract and Moderna poster say immune responses remained stable above baseline through 36 months, the vaccine was well tolerated, and no safety concerns were identified. That is a clearly positive framing for this study.

Sources
Web Searchsciencedirect.com11/1/25
A Phase 2 Extension Trial of the Safety and Immunogenicity of Cytomegalovirus mRNA-1647 Vaccine Through 36 Months in Healthy Adults

Abstract conclusion for this extension trial: immune responses remained stable from Months 24-36, exceeded baseline levels, and mRNA-1647 was well tolerated with no safety concerns identified.

View source
Sponsorq4cdn.com4/14/25
Long-Term Safety and Immunogenicity of Cytomegalovirus mRNA-1647 Vaccine in Healthy Adults: 36-Month Results

Moderna poster for NCT04975893 reports antibody responses remained stable through Month 36 and the safety profile was generally well tolerated, with no deaths, no discontinuations, and no related serious adverse events.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted92% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Exact Phase 2 extension trial NCT04975893 has a trial-specific favorable readout: both the journal abstract and Moderna poster say immune responses remained stable above baseline through 36 months, the vaccine was well tolerated, and no safety concerns were identified. That is a clearly positive framing for this study.

Found Apr 1, 2026, 6:37 PMOutcome date Apr 14, 2025, 12:00 AMReviewed Apr 1, 2026, 6:46 PM
Web Searchsciencedirect.comNov 1, 2025, 12:00 AM
A Phase 2 Extension Trial of the Safety and Immunogenicity of Cytomegalovirus mRNA-1647 Vaccine Through 36 Months in Healthy Adults
Abstract conclusion for this extension trial: immune responses remained stable from Months 24-36, exceeded baseline levels, and mRNA-1647 was well tolerated with no safety concerns identified.
Sponsorq4cdn.comApr 14, 2025, 12:00 AM
Long-Term Safety and Immunogenicity of Cytomegalovirus mRNA-1647 Vaccine in Healthy Adults: 36-Month Results
Moderna poster for NCT04975893 reports antibody responses remained stable through Month 36 and the safety profile was generally well tolerated, with no deaths, no discontinuations, and no related serious adverse events.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 6:46 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)92% confidenceReviewed Apr 1, 2026, 6:46 PM

Exact Phase 2 extension trial NCT04975893 has a trial-specific favorable readout: both the journal abstract and Moderna poster say immune responses remained stable above baseline through 36 months, the vaccine was well tolerated, and no safety concerns were identified. That is a clearly positive framing for this study.